
News|Videos|December 6, 2020
The Development and Treatment Potential of FTX-6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what FTX-6058 is, how it was developed, and what it is able to treat.
Advertisement
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham explains what FTX-6058 is, how it was developed, and what it is able to treat.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Off-Label: How Auvelity's Approval Changes Agitation Management in Alzheimer Disease
2
What Does the FDA Advisory Committee’s Vote on 7 Peptides Mean for Pharmacy Practice?
3
FDA Approves SimpleScreen CRC Blood Test for Colorectal Cancer Screening
4
What the Peptide Vote Actually Changes at My Counter (Hint: Not Much, Yet)
5











































































































